Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis.
about
Is the risk of cardiovascular disease altered with anti-inflammatory therapies? Insights from rheumatoid arthritisClosing the knowledge gap on cardiovascular disease in type 2 diabetes: the EMPA-REG OUTCOME trial and beyondBenefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-AnalysisSAVOR-TIMI to SUSTAIN-6: a critical comparison of cardiovascular outcome trials of antidiabetic drugs.Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta-analysis of data from randomized placebo-controlled trialsOsmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials.SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.Dose Modification of Antidiabetic Agents in Patients with Type 2 Diabetes Mellitus and Heart Failure.Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study.Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III StudiesDapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin.Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes.Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes.Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysisEmerging use of combination therapies for the management of type 2 diabetes - focus on saxagliptin and dapagliflozin.Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes.Pharmacokinetic drug evaluation of saxagliptin plus dapagliflozin for the treatment of type 2 diabetes.Changes in Glycemic Control and Body Weight After Initiation of Dapagliflozin or Basal Insulin Supported Oral Therapy in Type 2 Diabetes: A Primary Care Database Study.Cardioprotective effects of SGLT2 inhibitors are possibly associated with normalization of the circadian rhythm of blood pressure.An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus.Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics.Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes.SGLT2 inhibitor/DPP-4 inhibitor combination therapy - complementary mechanisms of action for management of type 2 diabetes mellitus.Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor.Cardiovascular disease prevention strategies for type 2 diabetes mellitus.Durability of response to dapagliflozin: a review of long-term efficacy and safety.Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease.The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice.Heart failure hospitalization risk associated with use of two classes of oral antidiabetic medications: an observational, real-world analysis.Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year.Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG).The Landscape of Glucose-Lowering Therapy and Cardiovascular Outcomes: From Barren Land to Metropolis.Dapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus.The effect of dapagliflozin treatment on epicardial adipose tissue volume.Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D).SGLT2 inhibitors: are they safe?Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes.Pharmacological management of type 2 diabetes: what's new in 2017?Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study.Un-sweetening the Heart: Possible pleiotropic effects of SGLT2 inhibitors on cardio and cerebrovascular alterations in resistant hypertensive subjects.
P2860
Q26746659-019C3DF5-6987-4528-8FB4-5C240DC759F6Q28075848-5A1B8667-1BB5-4394-B51D-73467F6A5E1EQ28553482-10CAC9C6-76EE-4998-BE30-3794D538F917Q30238791-C547D077-1AE1-4409-A5C0-8CC49CF57086Q31112303-3B9DE593-3076-47D2-ADB9-57CC7937DC8DQ33166813-E459C5B1-A0F7-4CD9-80C9-F06757B7A1E3Q33696974-F07D63B5-5EC8-42D3-9917-CDAC6F2F2988Q33815573-C90768A1-3DB5-48D0-BF83-8B2A2742E98AQ33882438-82737D4D-1AF4-46EA-8DCC-688E58D97943Q37075620-E86EF519-F27D-4CA9-A34E-BADA3204F245Q37586607-9A8122F0-4E7F-40E5-BA31-1812F4B34036Q37594479-8251CF9B-11FC-4D39-8F86-2AEC0EF35BCBQ37620904-BF3038C8-D715-42DB-A292-450FA3E34A0DQ37668253-5DCCB8FF-B312-4095-972F-AD64F6B5B980Q38645792-7278EF19-D565-485A-A593-678BFE71B68DQ38783203-526CA6FC-9D7B-4A8D-91AB-0D61B0C31CC3Q38856808-6CECEB45-AFD6-4FC9-8BFF-ADBE4074EAB8Q38903825-95BD8E40-258C-4073-B7A7-B410C248B813Q39013664-BC9E1B48-253C-4B55-AA80-FC74A863D93CQ39023661-5C6AADE0-4800-4CA6-A60E-8F60DADBF712Q39126658-7E324807-9520-44F8-8397-A64EA755EB43Q39170860-2194D3C4-87A2-4D80-A86B-30EB31E6E215Q39189383-BBB5612B-88D5-4672-BBA9-385B27F94FBAQ39255963-C407BE85-3C11-4492-A663-E4C9928A530CQ39420208-BFBEEB72-F662-4F54-B6F9-C9EAF653F7C8Q39430445-9B7B11D2-C313-49E1-A13D-E7AE5342B0FFQ39892657-DEA01F44-034B-4CBB-8DC7-4C9565152C8DQ40106543-9CE5BC43-F17F-4821-9174-88920BFCE5E6Q41176211-CC6DE276-CBB8-4841-89E9-9E20CA43312BQ41551599-110FA672-DFE1-4FC1-8742-C4B2C7FACF7BQ42643753-F46C6DF5-1470-4B4B-9ED9-25E01F01592FQ47117670-85DF6248-05D7-401A-A830-C050ED4F6364Q47137994-064186EB-597D-4AF8-9DF7-38A091F79AF1Q47142556-06EABC57-3882-4375-8C26-05F9A3404604Q47149127-B960A66C-D8A5-4CD6-9005-5F181EB36C03Q47642298-75A21108-539E-43D0-9A2B-09E9A5071554Q47687852-99375FF5-0DEC-4440-BF0B-A24F25D7E0E2Q47696671-DABA038C-E064-4799-B73A-29213D34EC2BQ48296619-74B36FDF-DFF0-4CBA-980D-F914A74F7A43Q49550551-00379B80-D539-4A80-9049-36012140BBCA
P2860
Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Cardiovascular effects of dapa ...... k categories: a meta-analysis.
@ast
Cardiovascular effects of dapa ...... k categories: a meta-analysis.
@en
type
label
Cardiovascular effects of dapa ...... k categories: a meta-analysis.
@ast
Cardiovascular effects of dapa ...... k categories: a meta-analysis.
@en
prefLabel
Cardiovascular effects of dapa ...... k categories: a meta-analysis.
@ast
Cardiovascular effects of dapa ...... k categories: a meta-analysis.
@en
P2093
P2860
P1476
Cardiovascular effects of dapa ...... k categories: a meta-analysis.
@en
P2093
Christian Sonesson
Eva Johnsson
Ingrid Gause-Nilsson
Peter A Johansson
P2860
P2888
P356
10.1186/S12933-016-0356-Y
P407
P577
2016-02-19T00:00:00Z
P5875
P6179
1053390135